Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Cerilliant
Novartis
Baxter
Boehringer Ingelheim
Merck
Johnson and Johnson
Moodys
Argus Health

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,173,037

« Back to Dashboard

Which drugs does patent 7,173,037 protect, and when does it expire?

Patent 7,173,037 protects ADEMPAS and is included in one NDA.

This patent has forty-one patent family members in thirty-five countries.
Summary for Patent: 7,173,037
Title:Carbamate-substituted pyrazolopyridines
Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
Inventor(s): Alonso-Alija; Cristina (Haan, DE), Bischoff; Erwin (Wuppertal, DE), Munter; Klaus (Wulfrath, DE), Stasch; Johannes-Peter (Solingen, DE), Stahl; Elke (Gladbach, DE), Weigand; Stefan (Wuppertal, DE), Feurer; Achim (Wilhelmsfeld, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/513,869
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,173,037

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-002 Oct 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-003 Oct 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-004 Oct 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-005 Oct 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,173,037

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 20 570May 8, 2002
PCT Information
PCT FiledApril 25, 2003PCT Application Number:PCT/EP03/04304
PCT Publication Date:November 20, 2003PCT Publication Number: WO03/095451

International Patents Family Members for US Patent 7,173,037

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway 20045277 ➤ Subscribe
Norway 329105 ➤ Subscribe
Netherlands 300659 ➤ Subscribe
Malaysia 136841 ➤ Subscribe
Mexico PA04011003 ➤ Subscribe
Luxembourg 92419 ➤ Subscribe
South Korea 101011864 ➤ Subscribe
South Korea 20050003415 ➤ Subscribe
Japan 4455321 ➤ Subscribe
Japan 2005531553 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Citi
Dow
Teva
Novartis
Medtronic
Fish and Richardson
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot